Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 115Cholangiocarcinoma 24Carcinoma, Renal Cell 20Liver Neoplasms 12Stomach Neoplasms 10Biliary Tract Neoplasms 10Thyroid Neoplasms 8Endometrial Neoplasms 8Breast Neoplasms 8Neoplasms 7Recurrence 6Neuroendocrine Tumors 5Neoplasm Metastasis 5Melanoma 5Uterine Cervical Neoplasms 4Thyroid Carcinoma, Anaplastic 4Thyroid Cancer, Papillary 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Liver Diseases 3Cirrhosis, Familial, with Pulmonary Hypertension 3Carcinoma, Adenoid Cystic 3Brain Neoplasms 3Advanced Biliary Tract Cancer 3Adenocarcinoma, Follicular 3Adenocarcinoma 3Uveal Melanoma 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2

Interventions

tislelizumab 1lenvatinib 1gemcitabine-oxaliplatin regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Potentially Resectable Locally Advanced Malignant Tumors of Biliary System × lenvatinib × Clear all
NCT05036798 2022-09-07

Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled
Gastrointestinal

Potentially Resectable Locally Advanced Malignant Tumors of Biliary System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡